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Abstract
Background: The aim of the study was to evaluate the association of two SNPs of EVER1/2 genes’ region
(rs2290907, rs16970849) and the FAS-670 polymorphism with the susceptibility to precancerous lesions and
cervical cancer in a Greek population.
Methods: Among the 515 women who were included in the statistical analysis, 113 belong to the case group and
present with precancerous lesions or cervical cancer (27 with persistent CIN1, 66 with CIN2/3 and 20 with cervical
cancer) and 402 belong to the control group. The chi-squared test was used to compare the case and the control
groups with an allelic and a genotype-based analysis.
Results: The results of the statistical analysis comparing the case and the control groups for all the SNPs tested were
not statistically significant. Borderline significant difference (p value = 0.079) was only found by the allelic
model between the control group and the CIN1/CIN2 patients’ subgroup for the polymorphism rs16970849.
The comparison of the other case subgroups with the control group did not show any statistically significant
difference.
Conclusions: None of the SNPs included in the study can be associated with statistical significance with the
development of precancerous lesions or cervical cancer.
Keywords: EVER, FAS, Polymorphism, Cervical cancer
Background
Cervical cancer is the third most commonly diagnosed
cancer and the fourth leading cause of cancer deaths in
women worldwide, accounting for 9% (529,800) of the
total new cancer cases and 8% (275,100) of the total
cancer deaths among females in 2008 [1]. Despite the
screening opportunities offered in the last decades,
cervical cancer still remains the second most common
type after breast cancer in the European Union in
women aged 15–44 years old [2]. The causal relation-
ship between human papillomavirus (HPV) infection
and the development of cervical cancer, originally pro-
posed by Prof Zur Hausen [3, 4], has been identified from
several studies as one of the highest risk ratios reported
for a specific cause of any major human cancer [5, 6].
However, the fact that only a small proportion of the
women infected with an oncogene HPV type develop
cervical cancer, indicates that other factors may play
an important role in the susceptibility for cervical
cancer, such as the genetic predisposition [7]. There
are several genetic variants associated with the persistence
of the HPV infection and the evolution to cervical cancer,
mainly by interfering with the host’s immune
response [8–10]. The EVER 1 and EVER2 genes (also
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referred to as TMC6 and TMC8 genes), located on
the chromosome 17q25 are two of the genetic poly-
morphisms which were recently related to cervical
cancer. These genes are most widely known for the
development of the rare autosomal recessive disease
of Epidermodysplasia Verruciformis (EV) which is
associated with extremely high sensitivity to HPV infec-
tions by HPV types belonging to the beta-genus [11].
Although the exact mechanism of this uncommon
susceptibility to HPV infections remains unknown, it
has been shown that loss-of-function mutations in
TMC6 or TMC8 genes play an important role in
most of the EV cases [12]. The TMC6 and TMC8
proteins seem to participate also in the regulation of
cellular zinc homeostasis in keratinocytes and lympho-
cytes, thus they can influence several signal transduction
pathways in different cell types [12, 13]. Concerning the
association of EVER1/2 genes with the development of
cervical cancer, Wang et al. studied 7140 single nucleotide
polymorphisms (SNPs) from 305 genes potentially related
to the DNA repair mechanisms, the HPV infection and
the entry of the HPV virus in the host cells [14]. The study
included 416 women with cervical intraepithelial neoplasia
grade 3 (CIN3) or cervical cancer, 356 women with per-
sistent HPV infection and 425 controls. The sample con-
sisted of women who participated in the population-based
cohort study of women in Guanacaste, Costa Rica [15]
and 331 supplemental CIN3 and cancer cases from
Guanacaste who were not participants in the natural
history study. The SNP rs9893818, which is located
near the EVER1/2 genes, was classified among the regions
that present a statistically significant association with the
progression of the HPV infection to CIN3/cervical
cancer [14]. Recently, Castro et al. analysed 22 SNPs
across an extended genomic region that harbours
TMC6 and TMC8 genes in 2989 patients with CIN3
(93%) or invasive cervical carcinoma (ICC) (7%) and
2281 controls from the Swedish population [16]. The
study included two Swedish cohorts. Cohort 1 was
based on a nested study within the Northern Sweden
Health and Disease Study Cohort [9]. Cohort 2 included
women from families with at least two affected women
from all of Sweden [17]. Two of the SNPs studied
(rs2290907 and rs16970849) were found to be significantly
correlated with cervical cancer (CIN3 and ICC) [16].
Another genetic locus widely studied in cervical
carcinogenesis is the encoding gene of the cell surface
death receptor FAS/CD95, which belongs to the wide
family of tumor necrosis factor (TNF) receptors. Although
cervical cancer cells can induce the tumor-specific cyto-
toxic T lymphocytes (CTLs) apoptosis, the fact that an
anti-CD95 antibody could block apoptosis, indicates that
tumor cells induce apoptosis of CTLs through CD95-CD95
ligand (FAS/FASL) interaction [18]. Cellular apoptosis plays
an important role in the human homeostasis and impaired
programmed cell death is necessary for tumorigenesis [19].
Therefore, the expression of the FAS/FASL genes may rep-
resent an important element in the susceptibility for
the development of cervical cancer. The most widely
analysed polymorphism in cervical carcinogenesis is
the FAS-670 gene promoter polymorphism (rs1800682).
The rs1800682 in the promoter of the FAS gene is located
within the consensus sequence of the STAT1 (signal
transducer and activator of transcription 1) transcription
factor binding site. The binding of the transcription factor
STAT1 to the FAS gene is associated with transcriptional
activation and expression of the FAS gene [20, 21]. An A
to G change at FAS-670 reduces the expression of the
FAS gene by abolishing the gamma interferon activation
signal binding site which results in decreased activation of
induced cell death [21].
The results of several studies analysing the role of the
FAS-670 gene promoter polymorphism in cervical
carcinogenesis are contradictory. According to the
studies of Nunobiki et al. and Ueda et al. in the Japanese
population, there is a higher G allele frequency in cases of
high-grade squamous intra-epithelial lesions (HSIL) com-
pared to low-grade squamous intra-epithelial lesions
(LSIL) [22–24]. There is also an increased OR for
GA + GG genotypes in HSIL cases compared to con-
trols, among women infected with high-risk HPV
types [22–24]. Similarly, a statistically significant correlation
between the susceptibility for cervical cancer and the AG
and combined AG+GG genotypes was observed in a study
referring to the Indian population [25]. The frequency of
the A allele and the AA genotype of the FAS-670
polymorphism was found to be higher in cases of
HSIL/cervical cancer in two studies of Lai et al. [26, 27].
The same polymorphism is associated with an increased
risk of cervical cancer in Brazilian women younger than
48 years old [28]. In contrast, no association between the
FAS-670 polymorphism and the susceptibility to cervical
cancer was shown by several studies in different popula-
tions published recently [29–31]. However, even without
being correlated with susceptibility to cervical cancer,
some genotypes of the FAS/FASL polymorphisms could
be related to the risk of lymph node metastasis of cervical
cancer [32].
The aim of our study was to evaluate the association
of two SNPs of EVER1/2 genes’ region (rs2290907,
rs16970849) as well as the FAS-670 polymorphism with
the susceptibility to precancerous lesions and cervical
cancer in a Greek population. The selection of the SNPs
rs2290907and rs16970849 was based on the results of
the study of Castro et al. [16] which confirmed a signifi-
cant correlation between these polymorphisms and
cervical cancer. The FAS-670 polymorphism was included
in the present study in order to enhance the already
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existing and quite contradictory data concerning its asso-
ciation with cervical cancer.
Methods
Study population
In total, 525 women participated in our study. Case sub-
jects were selected from patients treated between 2006
and 2011 at the University Clinics of Obstetrics and
Gynaecology in the Aristotle University of Thessaloniki in
Greece. The case group consisted of women with a
medical history of precancerous lesions or cervical
cancer. The control group contained healthy subjects
with a history of normal cervical cytology. The recruit-
ment of the sample and the classification between case
and control subjects was based on the medical history and
cytological findings of the participants, as well as their
first-degree relatives. The inclusion of the participants in
the case group was based on a histopathological diagnosis
of precancerous lesions or cervical cancer, while the
women belonging to the control group had a normal cer-
vical cytology throughout their regular annual screening.
Out of the 525 participants, 10 were excluded from the
statistical analysis as none of the three polymorphisms
were found in their genetic analysis. Among the 515
women who were finally included in the statistical ana-
lysis, 113 presented with precancerous lesions or cervical
cancer (27 with persistent CIN1, 66 with CIN2/3 and 20
with cervical cancer) and 402 were classified to the control
group. The age was not significantly different between the
case and the control group. The mean age for the case
group was 43.75 ± 16.33 years and the mean age for the
control group was 45.2 ± 17.23 years.
All the participants were subjected to a peripheral
blood test, while those that had not had a pap-test in the
last year were in addition subjected to cervical cytology.
The study was approved by the local ethical review
board of the Aristotle University of Thessaloniki, and all
participants provided written informed consent.
Genotyping
Genomic DNA extraction was carried out from 200 μl
of EDTA-anticoagulated whole blood using a QIAamp®
DNA Blood Mini Kit (Qiagen GmbH, Hilden, Germany)
according to the manufacturer’s protocol. The EVER1/
EVER2 (rs2290907 and rs16970849) and FAS-670
(rs1800682) SNPs were genotyped with TaqMan allele-
specific PCR amplification technology on an ABI PRISM
7900 Sequence Detection System (Applied Biosystems,
Foster City, USA) and analysed with the Sequence
Detection Software (SDS 2.1, Applied Biosystems,
Foster City, USA). Initially observed SNP allelic dis-
crimination curves of all genotypes were confirmed
by direct DNA sequencing on an ABI PRISM 3100
genetic analyser (Applied Biosystems, Foster City,
USA).
Regarding the linkage-disequilibrium (LD) with other
SNPs, according to the International HapMap Project,
the FAS gene has three LD blocks and rs1800682 is
located in the first LD block and therefore is in high
LD with other SNPs within this block. Similarly, the
TNRC6C gene has two LD blocks and rs2290907 is
located in the second large block. Finally, TMC8 gene
has four LD blocks and rs16970849 is located in the
last one.
Statistical analysis
A power analysis was performed using the CaTS Power
Calculator [33]. Taking into account the number of cases
and controls, our study had a power of 80% to detect
odds ratios of 1.53, 1.77 and 2.55 for rs1800682,
rs2290907 and rs1697084 respectively, assuming the
minor allele frequencies of each SNP in the TSI
population (Tuscan in Italy which is genetically closer
to our population).
Basic statistical analysis for genotype-disease association
was performed using the analysis tool PLINK (http://
pngu.mgh.harvard.edu/purcell/plink/) [34]. The initial
quality control tests included the calculation of the num-
ber of missing genotypes for each SNP and the assessment
of the Hardy–Weinberg equilibrium expectation for cases
and controls separately with a p value of 0.001 as the
significance threshold. In addition, the Minor Allele
Frequency (MAF) was estimated and a test looking for
distortion of Mendelian segregation was performed. None
of the SNPs were excluded according to the Hardy-
Weinberg equilibrium test or non-Mendelian segregation.
Once the quality tests were completed, a basic association
analysis on an SNP by SNP base was done, comparing
allele and genotype frequencies between cases and
controls. The Chi-Squared test was used for detecting
potential genotype-disease correlation and its
associated p-value, as well as the odds-ratio (OR), for
each SNP were calculated.
Results
The genetic characteristics (gene, chromosome, chromo-
somal position, distance from the gene start, location,
function and minor allele frequencies) of the three SNPs
included in our study, are summarised in Table 1. The
allelic as well as the genotype frequencies for all SNPs in
the case and control group are summarised in Table 2.
Table 3 shows the results of the chi-squared tests per-
formed to detect any association between the three SNPs
and the development of precancerous lesions or cervical
cancer. The large p values varying between 0.26 and 0.98
indicated no statistically significant differences between
the case and the control group for all the SNPs tested.
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The linear estimated effect sizes were 0.2, 2.2 and 55% for
SNPs rs1800682, rs2290907 and rs16970849 respectively.
None of them were significant.
The lack of association between the studied SNPs
and cervical cancer was further confirmed by the
large p values obtained by the genotype-based analysis
(Table 4) as well as the dominant and recessive model
analysis (Table 5). Both comparisons failed to detect
any statistically significant difference between the case
and the control group. At this point it should be
mentioned that no results were obtained for the
recessive model in the case of the SNP rs16970849,
due to the fact that there were no women with AA
genotype detected in the study sample.
A supplementary analysis was performed comparing
the control group with each one of the following sub-
groups: CIN1/CIN2, CIN2/CIN3 and CIN3/Cervical
cancer. Borderline significant difference (p value = 0.079)
was only found by the allelic model between the control
group and the CIN1/CIN2 patients’ subgroup for the
polymorphism rs16970849. No statistically significant
difference was detected by the comparison of the other
subgroups with the control group.
According to the results of the statistical analysis none
of the SNPs included in our study can be associated with
statistical significance with the development of precan-
cerous lesions or cervical cancer.
Discussion
The aim of our study was to evaluate the potential con-
tribution of certain EVER1/2 and FAS polymorphisms to
the susceptibility for cervical cancer. None of the three
SNPs investigated in the present study (rs1800682,
rs2290907 and rs16970849) present any statistically
significant association with the development of persistent
precancerous lesions or cervical cancer.
Current literature data regarding EVER genes presume
their participation in the control of the HPV life cycle
and pathogenesis as well as their influence on the host’s
immune responses and, therefore, its capacity for HPV
clearance [35, 36]. According to the model proposed by
Lazarczyck et al., the interaction between the E5 protein
of the HPV with the TMC/ZnT complex in keratinocytes
could lead to an increased level of intracellular free Zn2+
with a consequent increased activity of transcription fac-
tors and viral replication [37]. The regions of EVER1/
TMC6 and EVER2/TMC8 have been previously reported
as interesting candidate genes in persistent viral infec-
tions and cervical cancer [14]. The SNP-based analysis
of Wang et al. revealed a statistically significant asso-
ciation of the SNP rs9893818 with cervical precancer
and cancer, but not with HPV persistence [14].
The selection of the SNPs rs2290907and rs16970849
was based on the association of these polymorphisms
with susceptibility to cervical cancer, shown recently by
Castro et al. [16]. This was the largest study to date to
analyse the role of EVER polymorphisms in the develop-
ment of cervical cancer by examining the 58 kb genomic
region harbouring the TMC6 and TMC8 genes in the
Swedish population. The sample size of this study was
2989 cases and 2281 controls, with 93% of the cases
Table 1 Genetic characteristics of the SNPs rs1800682, rs2290907and rs16970849
SNP Gene Chromosome Chromosome Positiona Distance from gene start Gene position Function MAFb
rs1800682 FAS 10 90749963 325c 5′ upstream regulatory C (0.403)
rs2290907 TNRC6Cd 17 76093677 93483e Intron 18–19 No-coding G (0.115)
rs16970849 TMC8 17 76133908 8403f Intron 11–12 No-coding A (0.049)
aChromosome positions of each SNP based on dbSNP human build 138 and human genome build 37.5
bMAF: minor allele frequency based on HapMap data in CEU population
cDistance from FAS gene start (90750288)-forward strand
dTNRC6C: trinucleotide repeat containing 6C gene (4 kb distance from TMC6)
eDistance from TNRC6Cgene start (76000194)-forward strand (15.3 kb distant from TMC6 gene start)
fDistance fromTMC8 gene start (76125505)-forward strand
Table 2 Allelic and genotype frequencies for SNPs rs1800682,
rs2290907, rs16970849 in the control and case group
SNP Genotypes/alleles Controls, n (%) Cases, n (%)
rs1800682
Genotype TT 119 (0.318) 34 (0.315)
TC 161 (0.431) 47 (0.435)
CC 94 (0.251) 27 (0.250)
Allele T 399 (0.533) 115 (0.532)
C 349 (0.467) 101 (0.468)
rs2290907
Genotype AA 279 (0.722) 76 (0.710)
AG 94 (0.244) 28 (0.262)
GG 13 (0.034) 3 (0.028)
Allele A 652 (0.845) 180 (0.841)
G 120 (0.155) 34 (0.159)
rs16970849
Genotype GG 369 (0.946) 99 (0.917)
GA 21 (0.054) 9 (0.083)
AA 0 0
Allele G 759 (0.973) 207 (0.958)
A 21 (0.027) 9 (0.042)
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diagnosed with CIN3 and 7% with ICC. Among the 22
genotyped SNPs, rs2290907 and rs16970849 were found
to be significantly associated with cervical cancer
(rs2290907: OR GGvsAA = 0.6, 95% CI: 0.3–0.9, p = 0.02
and rs16970849: OR AGvsGG = 0.8, 95% CI: 0.66–0.98,
p = 0.03). In contrast to the study of Castro et al., our
study did not detect any statistically significant associ-
ation between these polymorphisms and susceptibility to
cervical cancer. The ethnically distinct populations could
be a possible explanation to the opposed results of the
two studies. In fact, the genotype frequencies of the SNP
rs16970849 in our sample were in the opposite direction
from that noted in the study of the Swedish population.
GG genotype was overrepresented in the control group
in our study (94.6%) and in the case group in the study
of Castro et al. (90.2%). This might reflect the differences
in the genetic background between the two populations.
Since this is the first study investigating the association
of the EVER genes with cervical cancer in a Greek popu-
lation, no other data from an ethnically similar sample
are available for comparison.
The FAS gene, belonging to the TNF receptors super-
family, has been related to an altered apoptosis proced-
ure and potential failure to induce apoptosis of HPV-
infected cells. The association between the cell surface
death receptor FAS and cervical cancer has been widely
studied in the past with most of the studies resulting in
conflicting findings. Two recent meta-analyses, per-
formed to clarify the already existing contradictory data,
show no association between the most investigated FAS-
670 polymorphism and susceptibility to cervical cancer
in Caucasian, Asian and African populations [38, 39].
Shen et al. included ten studies in the meta-analysis with
a total of 4,904 participants (2,317 cases and 2,587
controls). After calculating the ORs for the allele, the
homozygous, the dominant and the recessive genetic
models, they concluded that there is no association
between FAS-670 polymorphism and susceptibility to
cervical cancer in both Caucasian and Asian women
[38]. Similarly, the meta-analysis performed by Chen
et al., consisting of seven studies (1856 cervical
cancer patients and 2097 controls), showed a lack of
association of the FAS-670 polymorphism with
cervical cancer [39]. The findings of our study agree
with the conclusions of these two recently published
meta-analyses, validating the absence of association
between the FAS-670 promoter polymorphism and
susceptibility to persistent precancerous lesions and
development of cervical cancer in the Greek female
population.
To our knowledge this is the first study in the
Greek population. Since it was designed as a hospital-
based study and was performed in a relatively small
sample, the conclusions may be susceptible to selec-
tion bias. Furthermore, the inclusion of women with
precancerous lesions in the group of cases may not
have been as strong as a group of patients exclusively
with cervical cancer. Nevertheless, the aim of our
study was to detect any possible association of certain
polymorphisms with persistent HPV infection, which
could be seen in cases of precancerous lesions as well
as cases of cervical cancer. Finally, another type of
Table 3 Allelic-based analysis in the control and case group for the SNPs rs1800682, rs2290907, rs16970849




Chi-square test P value OR (95% CI)
rs1800682 0.4676 0.4666 0.0006938 0.979 1.004 (0.741–1.360)
rs2290907 0.1589 0.1554 0.01503 0.902 1.026 (0.678–1.554)
rs16970849 0.04167 0.02692 1.259 0.262 1.571 (0.709–3.483)
Table 4 Genotype-based analysis in the control and case group for the SNPs rs1800682, rs2290907, rs16970849
SNP Genotype Controls Cases p-value OR (95% CI)
rs1800682 aa(CC) 94(25.1%) 27(25.0%) 0.996 0.955(0.539–1.690)
Aa(TC) 161(43.1%) 47(43.5%) 1.022(0.619–1.686)
AA (TT) 119(31.8%) 34(31.5%) 1
rs2290907 aa(GG) 13(3.4%) 3(2.8%) 0.8994 0.847(0.235–3.049)
Aa(AG) 94(24.3%) 28(26.2%) 1.094(0.668–1.789)
AA(AA) 279(72.3%) 76(71.0%) 1
rs16970849 aa(AA) 0(0%) 0(0%) 0.2544 -
Aa(GA) 21(5.4%) 9(8.3%) 1.597(0.709–3.597)
AA(GG) 369(94.6%) 99(91.7%) 1
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limitation to consider is the small sample size of our
study, which could not allow the declaration of a null
result from the present study.
Conclusions
The present study did not show any significant asso-
ciation of the EVER1/2 polymorphisms (rs2290907and
rs16970849) with cervical cancer. However, it does
provide additional data favouring no association
between the FAS polymorphism (rs1800682) and the
susceptibility to persistent precancerous lesions and
cervical cancer. Current literature data for EVER1/2
polymorphisms and cervical cancer are very limited
worldwide, therefore larger scale prospective studies
are necessary in order to further clarify the role of
these polymorphisms in cervical carcinogenesis.
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